Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)
Non-valvular Atrial Fibrillation
About this trial
This is an interventional supportive care trial for Non-valvular Atrial Fibrillation focused on measuring apixaban, atrial fibrillation
Eligibility Criteria
Inclusion Criteria:
- Non-valvular atrial fibrillation that is either paroxysmal, persistent or permanent
- CHA2DS2VASc score of 2 or more
- Eligible for therapy with apixaban for at least 6 months
- Possession of a smartphone capable of pairing with the AliveCor Kardia cardiac monitor
Exclusion Criteria:
- Contraindication to anticoagulation with apixaban for at least 6 months
- No access to a smartphone capable of pairing with the AliveCor Kardia cardiac monitor
- Unable to provide informed consent for this protocol
Sites / Locations
- Saint Luke's Health System
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Experimental
Control
In the experimental group, each patient will be issued an AliveCor Kardia electrocardiogram monitor that is compatible with their smartphone. Patients will be instructed on the use of the monitor at the initial visit with the study nurse. The patient will submit daily electrocardiogram transmission via on online portal. The study nurse may contact them via text message to remind them to submit their recordings, if they forget. The remainder of the treatment of the experimental group will be identical to the control group. At the conclusion of the study, the patient will complete their final atrial fibrillation symptom assessment scale. Their smartphone electrocardiogram monitor will be reviewed to ensure that all of the recordings were retrieved successfully.
Patients in the control group would receive the standard of care treatment for atrial fibrillation, including cardioversion and ablation as indicated. At monthly visits with the study nurse, a smartphone electrocardiogram monitor will be used to record patient's heart rhythm. No other intervention would be performed during the monthly visit. It is necessary to meet the subject at least once per month to receive the previous month's supply of pills and provide them with the next month's supply of pills. If these subjects were met less frequently, it is possible that the previous month's supply of pills might be lost by the end of the study. During the study, if the patient is taken off anticoagulation due to medical contraindication or after an ablation, they will continue to be followed monthly but will not receive apixaban medication.